NCT06988124 Dexamethasone Palmitate for PONV After Craniotomy
| NCT ID | NCT06988124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Postoperative Nausea and Vomiting |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-06-25 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-06-25 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 65 years; * Providing written informed consent; * Perform elective craniotomy undergoing general anesthesia. Exclusion Criteria: * Known to be allergic to dexamethasone; * Any systemic glucocorticoids within 3 months before trial entry; * History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al); * Cognitive impairment or severe mental illness; * Uncontrolled diabetes or infectious diseases; * Pregnancy or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06988124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Postoperative Nausea and Vomiting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06988124 currently recruiting?
Yes, NCT06988124 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT06988124 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06988124 clinical trial?
NCT06988124 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 500 participants.